ImmTOR™ Chronic Refractory Gout Therapy Program: Publications & Posters
Antigen-selective modulation of AAV immunogenicity with tolerogenic rapamycin nanoparticles enables successful vector readministration
Meliani A, Boisgerault F, Hardet R, et al.
Tolerogenic ImmTOR™ nanoparticles enhance vector transduction, mRNA synthesis and transgene expression after initial and repeated administrations of AAV-based gene therapy vectors
Ilyinskii P, et al.
Mitigation of inflammation induced by monosodium urate crystals in mice by treatment with SVP-rapamycin
Pallavi Kolte, Robert LaMothe, Joseph Ferrari, Sheldon Leung, Wesley DeHaan, Earl Sands, and Takashi Kei Kishimoto
Antigen-specific modulation of capsid immunogenicity with tolerogenic nanoparticles results in successful AAV vector readministration
Takashi Kei Kishimoto, Amine Meliani, Fanny Collaud, Christian Leborgne, Ronzitti Guiseppe, Florence Boisgerault, and Federico Mingozzi